Treanda (bendamustine hydrochloride) Solution by Teva: FDA Statement - Not Compatible with Closed System Transfer Devices, Adapters, and Syringes Containing Polycarbonate or Acrylonitrile-Butadiene-Styrene
Can lead to device failure, possible product contamination, and potential serious adverse health consequences. (Source: FDA MedWatch)
Source: FDA MedWatch - March 11, 2015 Category: American Health Source Type: news
Teva to commercialise Eagle's cancer drug in US
Israel-based Teva Pharmaceutical Industries has signed an exclusive licence agreement with Eagle Pharmaceuticals for its bendamustine hydrochloride (HCl) rapid infusion product. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 18, 2015 Category: Pharmaceuticals Source Type: news
ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL
Improved progression - free survival with ibrutinib for older adults with untreated CLL (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news
Cornerstone begins Phase I trial of lymphoma drug candidate CPI-613
Cornerstone Pharmaceuticals has started a Phase I clinical trial of its lead drug candidate CPI-613, in combination with bendamustine (Treanda), to treat patients with relapsed or refractory classic Hodgkin's lymphoma (HL) or T-cell non-Hodgkin's lym… (Source: Drug Development Technology)
Source: Drug Development Technology - October 22, 2014 Category: Pharmaceuticals Source Type: news
GSK and Genmab receive European approval for Arzerra
GlaxoSmithKline (GSK) and Genmab have received European Commission marketing authorisation for Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 3, 2014 Category: Pharmaceuticals Source Type: news
Ofatumumab Now Has Full European Union Authorization for CLLOfatumumab Now Has Full European Union Authorization for CLL
The drug now has full European Union authorization for use in chronic lymphocytic leukemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
GSK and Genmab receive EU authorisation for Arzerra™ (ofatumumab) as first-line treatment for chronic lymphocytic leukaemia (CLL) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the European Commission (EC) has granted marketing authorisation for a new indication for the use of Arzerra™. (Source: GSK news)
Source: GSK news - July 3, 2014 Category: Pharmaceuticals Source Type: news
GSK and Genmab receive CHMP positive opinion for Arzerra (ofatumumab) in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who are not eligible for fludarabine-based therapy
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorisation for Arzerra™ (ofatumumab) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. (Source: GSK news)
Source: GSK news - May 23, 2014 Category: Pharmaceuticals Source Type: news
Study Finds New Chemo Combo May be Better for Some Non-Hodgkin’s...
Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas.(PRWeb March 12, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11642851.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2014 Category: Pharmaceuticals Source Type: news
Glenmark faces patent infringement suit in US
Glenmark Pharmaceuticals has been slapped with a patent infringement case by US-based Cephalon Inc to sell generic version of Treanda. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 31, 2013 Category: Pharmaceuticals Source Type: news
Older Patients With CLL Receiving BendamustineOlder Patients With CLL Receiving Bendamustine
Find out more about the synergy of bendamustine and rituximab in chronic lymphocytic leukemia. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Genmab reports top-line results from Phase II CLL study of ofatumumab
Genmab has reported top-line results from a Phase II study of ofatumumab combined with bendamustine in untreated and relapsed chronic lymphocytic leukemia (CLL). (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2013 Category: Pharmaceuticals Source Type: news
Bendamustine Plus Rituximab Boost PFS in Indolent LymphomasBendamustine Plus Rituximab Boost PFS in Indolent Lymphomas
The combination of bendamustine plus rituximab appears to be more effective and less toxic than standard therapy in indolent lymphomas. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Bendamustine data published in The Lancet
Results from the StiL NHL-1 study published in The Lancet show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 22, 2013 Category: Drugs & Pharmacology Source Type: news
